dividend growth
The major Canadian and U.S. stock markets have moved back up since their initial COVID-19 drop. Nonetheless, we think that if you can afford to stay in the market for several years or longer, now is still a good time for new buying. We see ETFs as one way for you to profit from the continuing rise, while at the same time cutting your risk....
Low interest rates have pushed income-seeking investors to search for high yield outside of traditional fixed-income investments. For many of these investors, stocks with high yields look increasingly attractive—and the best of those stocks (or ETFs that hold them) are buys for current income, as well as the potential for capital gains.
In some cases, however, a high yield may be a warning sign that all is not well with a company and that future dividend payments are at risk....
In some cases, however, a high yield may be a warning sign that all is not well with a company and that future dividend payments are at risk....
The major Canadian and U.S. stock markets have moved back up since their initial COVID-19 drop. Nonetheless, we think that if you can afford to stay in the market for several years or longer, now is still a good time to buy. We see ETFs as one way for you to profit from that rise, while cutting your risk.
The best of these funds offer a diversified group of stocks while charging you low management fees....
The best of these funds offer a diversified group of stocks while charging you low management fees....
The most profitable stocks to invest in for your diversified portfolio will include not just blue chips, but also top growth stocks
A: BMO International Dividend ETF, $19.67, symbol ZDI on Toronto (Units outstanding: 22.2 million; Market cap: $440.6 million; www.bmo.com), offers exposure to a portfolio of high-yield dividend-paying companies in developed market....
Include high-quality dividend-paying stocks in your portfolio to cut risk while at the same time generating both capital gains and income
We have singled out two stocks and one ETF as your #1 buys for 2021. Each offers investors long-term growth prospects at a reasonable price. Meanwhile, all three are in a strong position to weather the current wave of COVID-19. Moreover, each is poised for solid gains as new vaccines help kick-start global economic growth.
ENBRIDGE $44.66 is a #1 Buy for 2021. The firm (Toronto symbol ENB; Shares outstanding: 2.0 billion; Market cap: $89.4 billion; TSINetwork Rating: Above Average; Dividend yield: 7.5%; www.enbridge.com) operates pipelines that pump Western Canadian oil and gas to eastern Canada and the U.S....
ENBRIDGE $44.66 is a #1 Buy for 2021. The firm (Toronto symbol ENB; Shares outstanding: 2.0 billion; Market cap: $89.4 billion; TSINetwork Rating: Above Average; Dividend yield: 7.5%; www.enbridge.com) operates pipelines that pump Western Canadian oil and gas to eastern Canada and the U.S....
The major Canadian and U.S. stock markets have moved back up since their initial COVID-19 drop. Nonetheless, we think that if you can afford to stay in the market for several years or longer, now is still a good time to buy. We see ETFs as one way for you to profit from that rise, while cutting your risk.
The best of these funds offer a diversified group of stocks while charging you low management fees....
The best of these funds offer a diversified group of stocks while charging you low management fees....
High fees, often not directly visible to investors, can substantially lower investment returns over time. It is therefore key that investors carefully consider fees before deciding to buy an ETF or mutual fund.
The following example demonstrates the outcome of a $100,000 investment in two identical vehicles that both produce an annual return of 10%....
The damaging effect of high fees
The following example demonstrates the outcome of a $100,000 investment in two identical vehicles that both produce an annual return of 10%....
We continue to see attractive investment opportunities in drug stocks. COVID-19 gave it a boost, of course. But the industry was already going to prosper, thanks to ongoing regulatory and research developments. Still, due to the nature of the business, results will vary widely and unpredictably from one drug company to another....